{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:28Z","timestamp":1787028628967,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Rheumatism Association","award":["R-941095"],"award-info":[{"award-number":["R-941095"]}]},{"name":"Swedish Rheumatism Association","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Swedish Rheumatism Association","award":["2020-00368"],"award-info":[{"award-number":["2020-00368"]}]},{"name":"Swedish Rheumatism Association","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"Swedish Rheumatism Association","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Swedish Rheumatism Association","award":["20181129NGBV"],"award-info":[{"award-number":["20181129NGBV"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["R-941095"],"award-info":[{"award-number":["R-941095"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["2020-00368"],"award-info":[{"award-number":["2020-00368"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"King Gustaf V\u2019s 80-year Foundation","award":["20181129NGBV"],"award-info":[{"award-number":["20181129NGBV"]}]},{"name":"Professor Nanna Svartz Foundation","award":["R-941095"],"award-info":[{"award-number":["R-941095"]}]},{"name":"Professor Nanna Svartz Foundation","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Professor Nanna Svartz Foundation","award":["2020-00368"],"award-info":[{"award-number":["2020-00368"]}]},{"name":"Professor Nanna Svartz Foundation","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"Professor Nanna Svartz Foundation","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Professor Nanna Svartz Foundation","award":["20181129NGBV"],"award-info":[{"award-number":["20181129NGBV"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["R-941095"],"award-info":[{"award-number":["R-941095"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2020-00368"],"award-info":[{"award-number":["2020-00368"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["20181129NGBV"],"award-info":[{"award-number":["20181129NGBV"]}]},{"name":"Region Stockholm","award":["R-941095"],"award-info":[{"award-number":["R-941095"]}]},{"name":"Region Stockholm","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Region Stockholm","award":["2020-00368"],"award-info":[{"award-number":["2020-00368"]}]},{"name":"Region Stockholm","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"Region Stockholm","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Region Stockholm","award":["20181129NGBV"],"award-info":[{"award-number":["20181129NGBV"]}]},{"name":"Karolinska Institutet","award":["R-941095"],"award-info":[{"award-number":["R-941095"]}]},{"name":"Karolinska Institutet","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Karolinska Institutet","award":["2020-00368"],"award-info":[{"award-number":["2020-00368"]}]},{"name":"Karolinska Institutet","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"Karolinska Institutet","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Karolinska Institutet","award":["20181129NGBV"],"award-info":[{"award-number":["20181129NGBV"]}]},{"name":"Nordic Pharma","award":["R-941095"],"award-info":[{"award-number":["R-941095"]}]},{"name":"Nordic Pharma","award":["FAI-2020-0741"],"award-info":[{"award-number":["FAI-2020-0741"]}]},{"name":"Nordic Pharma","award":["2020-00368"],"award-info":[{"award-number":["2020-00368"]}]},{"name":"Nordic Pharma","award":["2021\u201326"],"award-info":[{"award-number":["2021\u201326"]}]},{"name":"Nordic Pharma","award":["FoUI-955483"],"award-info":[{"award-number":["FoUI-955483"]}]},{"name":"Nordic Pharma","award":["20181129NGBV"],"award-info":[{"award-number":["20181129NGBV"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We investigated B-cell-activating factor (BAFF) in relation to response to treatment with TNF inhibitors (TNFis) in rheumatoid arthritis (RA). This was a longitudinal study including 158 patients with RA treated with TNFis and followed up for 6 months. Clinical response at 6 months of treatment was defined according to the EULAR criteria for good responders (GRs). BAFF concentration was measured in serum samples, collected at baseline and at 6 months. Associations with EULAR response were evaluated using univariable and multivariable logistic regression models. ROC analysis was performed to determine the optimal threshold of serum BAFF concentration associated with good EULAR response to treatment. After 6 months of TNFi treatment, 24% of patients were GRs. They had a lower BMI, lower baseline DAS28 and lower baseline serum BAFF concentration than non-responders. After 6 months of TNFi treatment, autoantibody-positive patients who attained GR had significantly lower serum BAFF concentrations compared with patients who did not. Serum BAFF &lt; 968 pg\/mL at 6 months represented the concentration likely to best discriminate between GR and non-GR at 6 months of TNFi treatment. Autoantibody-seropositive patients who had serum BAFF &lt; 968 pg\/mL at 6 months demonstrated a more than four-fold increased probability to be GRs compared with patients with higher BAFF concentrations. In conclusion, serum BAFF concentrations were associated with response to TNFis in seropositive RA patients, corroborating the importance of the B-cell compartment in RA.<\/jats:p>","DOI":"10.3390\/jcm11175207","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T20:52:51Z","timestamp":1662497571000},"page":"5207","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-3312","authenticated-orcid":false,"given":"Borja","family":"Hern\u00e1ndez-Breijo","sequence":"first","affiliation":[{"name":"Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 17176 Stockholm, Sweden"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, 17176 Stockholm, Sweden"},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University, 70182 \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-0859","authenticated-orcid":false,"given":"Marta","family":"Novella-Navarro","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"},{"name":"Rheumatology, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5580-8387","authenticated-orcid":false,"given":"Ana","family":"Mart\u00ednez-Feito","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"},{"name":"Immunology Unit, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"},{"name":"Rheumatology, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"D\u00edaz-Almir\u00f3n","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Pascual-Salcedo","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"},{"name":"Rheumatology, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamaida","family":"Plasencia-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, 28046 Madrid, Spain"},{"name":"Rheumatology, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"ref_1","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: A systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10067-017-3639-0","article-title":"Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis","volume":"37","author":"Xie","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJMe2018218","article-title":"PRIME Time in Rheumatoid Arthritis","volume":"383","author":"Gravallese","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa2004114","article-title":"RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares","volume":"383","author":"Orange","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.1102321","article-title":"Soluble BAFF Levels Inversely Correlate with Peripheral B Cell Numbers and the Expression of BAFF Receptors","volume":"188","author":"Kreuzaler","year":"2012","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF Overexpression Is Associated with Autoantibody Production in Autoimmune Diseases","volume":"1050","author":"Pers","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/cei.13542","article-title":"Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD)","volume":"203","author":"Pouw","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_9","first-page":"1256","article-title":"Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis","volume":"35","author":"Bosello","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3918","article-title":"B-cell selection and the development of autoantibodies","volume":"14","author":"Giltiay","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_11","first-page":"691","article-title":"Association between autoantibody level and disease activity in rheumatoid arthritis is dependent on baseline inflammation","volume":"38","author":"Pongratz","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s10067-019-04626-x","article-title":"Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis","volume":"38","author":"Ogawa","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/annrheumdis-2012-201517","article-title":"Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity","volume":"72","author":"Aletaha","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13075-020-02354-1","article-title":"Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis","volume":"22","author":"Plasencia","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_16","first-page":"279","article-title":"2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis","volume":"11","author":"Andreu","year":"2015","journal-title":"Reumatol. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League against Rheumatism Criteria","volume":"39","author":"Prevoo","year":"1996","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF Rescues Self-Reactive B Cells from Peripheral Deletion and Allows Them to Enter Forbidden Follicular and Marginal Zone Niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3389\/fimmu.2018.02871","article-title":"Interleukin-33 Contributes toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production","volume":"9","author":"Rose","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: Results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1874312901408010073","article-title":"Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor","volume":"8","author":"Aberumand","year":"2014","journal-title":"Open Rheumatol. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1002\/jcp.28445","article-title":"The role of BAFF and APRIL in rheumatoid arthritis","volume":"234","author":"Shabgah","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/ar2809","article-title":"Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis","volume":"11","author":"Leandro","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar4543","article-title":"High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study","volume":"16","author":"Daien","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3389\/fimmu.2020.01913","article-title":"Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis","volume":"11","author":"Sobrino","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"683990","DOI":"10.3389\/fmed.2021.683990","article-title":"Remission Induced by TNF Inhibitors Plus Methotrexate is Associated with Changes in Peripheral Na\u00efve B Cells in Patients with Rheumatoid Arthritis","volume":"8","author":"Sobrino","year":"2021","journal-title":"Front. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11632","DOI":"10.1038\/s41598-021-91177-4","article-title":"BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors","volume":"11","author":"Parodis","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1756-185X.2012.01754.x","article-title":"Measures in rheumatoid arthritis: Are we measuring too many parameters","volume":"15","author":"Chandrashekara","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_31","first-page":"216","article-title":"Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis","volume":"66","author":"Pincus","year":"2008","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/rheumatology\/kem286","article-title":"Inter-observer agreement of standard joint counts in early rheumatoid arthritis: A comparison with grey scale ultrasonography a preliminary study","volume":"47","author":"Salaffi","year":"2008","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2017.07.019","article-title":"Biomarkers as a treatment guide in rheumatoid arthritis","volume":"186","author":"Takeuchi","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/14712598.2012.758248","article-title":"Belimumab\u2014An anti-BLyS human monoclonal antibody for rheumatoid arthritis","volume":"13","author":"Jin","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/17\/5207\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:40Z","timestamp":1760142160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/17\/5207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":36,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["jcm11175207"],"URL":"https:\/\/doi.org\/10.3390\/jcm11175207","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}